Langlai Technology (朗来科技)

Createrna (Langlai Technology) is a Wuhan-based innovative drug R&D company founded in 2013 that develops oral small-molecule therapies for chronic diseases, with programs across inflammatory/immunology, cardio-renal, respiratory and ophthalmic indications. Its integrated pipeline spans 16 self-developed assets, and its first approved product, the oral complement factor B inhibitor lanoracopan hydrochloride (MY008211A) for paroxysmal nocturnal hemoglobinuria, was approved in China in June 2026. Ex-China rights to its clinical-stage asset ABBV-848 are held by AbbVie, per the AbbVie Q1 2026 earnings call.

  • Series B
  • Biotechnology
  • Clinical Trials
  • Healthtech
  • Pharmaceuticals
  • Healthcare & Life Sciences

1

Round

1

Industry

5

Tags

Nov 13, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 13, 2026

    Series B

    Led by PICC Capital

    • Qianhai Ark
    • Vivo Capital
    • PICC Capital
    • China Merchants Capital
    • GF Qianhe
    • Changjiang Capital
    • NEXTBIO MASTER FUND LP

    Langlai Technology (Createrna) Raises Series B Led by PICC Capital

    Langlai Technology (Createrna) Raises Series B Led by PICC Capital Langlai Technology (朗来科技), which operates as Createrna, has raised a Series B round led by P…

    Read article

Pricing

Research Langlai Technology (朗来科技) — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Langlai Technology (朗来科技) is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational